Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $351.00 at Citigroup

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target upped by Citigroup from $338.00 to $351.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on ALNY. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday. Needham & Company LLC restated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Chardan Capital restated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Finally, Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Stock Up 11.8 %

Alnylam Pharmaceuticals stock opened at $283.34 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm’s fifty day moving average is $257.16 and its 200 day moving average is $259.65. The company has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital World Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after buying an additional 92,101 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after buying an additional 98,303 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.